Inhibitors of sodium-glucose cotransporter 2 (SGLT2) is a novel anti-diabetes drug, which reduces blood glucose by increasing urinary glucose excretion. Recently, a number of clinical trials in other countries have indicated that SGLT2-inhibitors may affect bone metabolism, bone mass and fracture risk in T2DM patients. Summarizing research in both China and overseas, our review focuses on the relationship between SGLT2 inhibitors and skeleton system in T2DM patients.